Silencing of the p18INK4c gene by promoter hypermethylation in Reed-Sternberg cells in Hodgkin lymphomas

Blood

Volumn 103, Issue 6, 2004, Pages 2351-2357

  Sánchez Aguilera, Abel ^b   Delgado, Julio ^b   Camacho, Francisca I ^b   Sánchez Beato, Margarita ^b   Sánchez, Lydia ^b   Montalbán, Carlos ^b   Fresno, Manuel F ^b   Martín, Carmen ^b   Piris, Miguel A ^b   García, Juan F ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P18; CDKN2C PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2C; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; B LYMPHOCYTE; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CELL CYCLE; CELL DIFFERENTIATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA METHYLATION; DNA MICROARRAY; ENZYME ACTIVITY; FOLLOW UP; GENE DISRUPTION; GENE EXPRESSION; GENE INACTIVATION; GENE REPRESSION; GENE SEQUENCE; GENE SILENCING; GERMINAL CENTER; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; REED STERNBERG CELL; SEQUENCE ANALYSIS; TUMOR SUPPRESSOR GENE; GENE EXPRESSION REGULATION; GENETICS; LYMPHOID TISSUE; MORTALITY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RETROSPECTIVE STUDY; RNA SPLICING; TUMOR CELL LINE;

CELL CYCLE PROTEINS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P18; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HODGKIN DISEASE; HUMANS; LYMPHOID TISSUE; PROMOTER REGIONS (GENETICS); REED-STERNBERG CELLS; RETROSPECTIVE STUDIES; RNA SPLICING; TUMOR SUPPRESSOR PROTEINS;

EID: 1542313894     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-07-2356     Document Type: Article

References (41)

1. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13:1501-1512.
2. Sanchez-Beato M, Sanchez-Aguilera A, Piris MA. Cell cycle deregulation in B-cell lymphomas. Blood. 2003;101:1220-1235.
3. Cairns P, Polascik TJ, Eby Y, et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet. 1995;11:210-212.
4. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res. 2001;61:3225-3229.
5. Villuendas R, Sanchez-Beato M, Martinez JC, et al. Loss of p16/INK4A protein expression in non-Hodgkin's lymphomas is a frequent finding associated with tumor progression. Am J Pathol. 1998; 153:887-897.
6. Herman JG, Civin CI, Issa JP, Collector MI, Sharkis SJ, Baylin SB. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res. 1997;57:837-841.
7. Martinez-Delgado B, Richart A, Garcia MJ, et al. Hypermethylation of P16ink4a and P15ink4b genes as a marker of disease in the follow-up of non-Hodgkin's lymphomas. Br J Haematol. 2000; 109:97-103.
8. Garcia JF, Villuendas R, Algara P, et al. Loss of p16 protein expression associated with methylation of the p16INK4A gene is a frequent finding in Hodgkin's disease. Lab Invest. 1999;79:1453-1459.
9. Garcia MJ, Martinez-Delgado B, Cebrian A, Martinez A, Benitez J, Rivas C. Different incidence and pattern of p15INK4b and p16INK4a promoter region hypermethylation in Hodgkin's and CD30-positive non-Hodgkin's lymphomas. Am J Pathol. 2002;161:1007-1013.
10. Stranks G, Height SE, Mitchell P, et al. Deletions and rearrangement of CDKN2 in lymphoid malignancy. Blood. 1995;85:893-901.
11. Otsuki T, Clark HM, Wellmann A, Jaffe ES, Raffeld M. Involvement of CDKN2 (p16INKA1 MTS1) and p15INK4B/MTS2 in human leukemias and lymphomas. Cancer Res. 1995;55:1436-1440.
12. Drexler HG. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia. 1998;12:845-859.
13. Guan KL, Jenkins CW, Li Y, et al. Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev. 1994;8:2939-2952.
14. Latres E, Malumbres M, Sotillo R, et al. Limited overlapping roles of P15(INK4b) and P18(INK4c) cell cycle inhibitors in proliferation and tumorigenesis. Embo J. 2000;19:3496-3506.
15. Franklin DS, Godfrey VL, Lee H, et al. CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes Dev. 1998;12:2899-2911.
16. Iolascon A, Faienza MF, Coppola B, della Ragione F, Schettini F, Biondi A. Homozygous deletions of cyclin-dependent kinase inhibitor genes, p16(INK4A) and p18, in childhood T cell lineage acute lymphoblastic leukemias. Leukemia. 1996; 10:255-260.
17. Williams ME, Whitefield M, Swerdlow SH. Analysis of the cyclin-dependent kinase inhibitors p18 and p19 in mantle-cell lymphoma and chronic lymphocytic leukemia. Ann Oncol. 1997;8:71-73.
18. Blais A, Labrie Y, Pouliot F, Lachance Y, Labrie C. Structure of the gene encoding the human cyclin-dependent kinase inhibitor p18 and mutational analysis in breast cancer. Biochem Biophys Res Commun. 1998;247:146-153.
19. Morse L, Chen D, Franklin D, Xiong Y, Chen-Kiang S. Induction of cell cycle arrest and B cell terminal differentiation by CDK inhibitor p18(INK4c) and IL-6. Immunity. 1997;6:47-56.
20. Tourigny MR, Ursini-Siegel J, Lee H, et al. CDK inhibitor p18(INK4c) is required for the generation of functional plasma cells. Immunity. 2002;17: 179-189.
21. Otsuki T, Jaffe ES, Wellmann A, Kumar S, Condron KS, Raffeld M. Absence of p18 mutations or deletions in lymphoid malignancies. Leukemia. 1996;10:356-360.
22. Siebert R, Willers CP, Fossa A, et al. Analysis of the novel cyclin-dependent kinase 4 and 6 inhibitor gene p18 in lymphoma and leukemia cell lines. Leuk Res. 1996;20:197-200.
23. Tasaka T, Berenson J, Vescio R, et al. Analysis of the p16INK4A, p15INK4B and p18INK4C genes in multiple myeloma. Br J Haematol. 1997;96:98-102.
24. Kulkami MS, Daggett JL, Bender TP, Kuehl WM, Bergsagel PL, Williams ME. Frequent inactivation of the cyclin-dependent kinase inhibitor p18 by homozygous deletion in multiple myeloma cell lines: ectopic p18 expression inhibits growth and induces apoptosis. Leukemia. 2002;16:127-134.
25. Garcia JF, Camacho FI, Morente M, et al. Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood. 2003;101:681-689.
26. Hertel CB, Zhou XG, Hamilton-Dutoit SJ, Junker S. Loss of B cell identity correlates with loss of B cell-specific transcription factors in Hodgkin/Reed-Sternberg cells of classical Hodgkin lymphoma. Oncogene. 2002;21:4908-4920.
27. Schwering I, Brauninger A, Klein U, et al. Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood. 2003;101:1505-1512.
28. Jaffe ES, Harris, NL, Stein H, Vardiman JW, eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues: World Health Organization Classification of Tumours. Lyon, France: IARC Press; 2001.
29. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4: 844-847.
30. Hedvat CV, Hegde A, Chaganti RS, et al. Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma. Hum Pathol. 2002;33:968-974.
31. Tzankov A, Zimpfer A, Lugli A, et al. High-throughput tissue microarray analysis of G1-cyclin alterations in classical Hodgkin's lymphoma indicates overexpression of cyclin E1. J Pathol. 2003;199:201-207.
32. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996;93:9821-9826.
33. Frommer M, McDonald LE, Millar DS, et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci U S A. 1992;89:1827-1831.
34. Millar DS, Warnecke PM, Melki JR, Clark SJ. Methylation sequencing from limiting DNA: embryonic, fixed, and microdissected cells. Methods. 2002;27:108-113.
35. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease: International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998;339:1506-1514.
36. Hinz M, Loser P, Mathas S, Krappmann D, Dorken B, Scheidereit C. Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Stemberg cells. Blood. 2001;97:2798-2807.
37. Kuppers R, Hansmann ML, Rajewsky K. Clonality and germinal centre B-cell derivation of Hodgkin/Reed-Sternberg cells in Hodgkin's disease. Ann Oncol. 1998;9(suppl 5):S17-S20.
38. Jundt F, Kley K, Anagnostopoulos I, et al. Loss of PU.1 expression is associated with defective immunoglobulin transcription in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease. Blood. 2002;99:3060-3062.
39. Bai F, Pei XH, Godfrey VL, Xiong Y. Haploinsufficiency of p18(INK4c) sensitizes mice to carcinogen-induced tumorigenesis. Mol Cell Biol. 2003; 23:1269-1277.
40. Kovalev GI, Franklin DS, Coffield VM, Xiong Y, Su L. An important role of CDK inhibitor p18(INK4c) in modulating antigen receptor-mediated T cell proliferation. J Immunol. 2001;167:3285-3292.
41. Blais A, Monte D, Pouliot F, Labrie C. Regulation of the human cyclin-dependent kinase inhibitor p18INK4c by the transcription factors E2F1 and Sp1. J Biol Chem. 2002;277:31679-31693.